Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis

Marcella, Stefanie; Welsh, Belinda; Foley, Peter

doi:10.1111/j.1440-0960.2010.00660.x

Cited by 21 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The coexistence of sarcoidosis and psoriasis also has been reported in both case series and population-based cohorts, which is hypothesized to occur as a result of overlapping pathogenetic mechanisms. [58][59][60] Lichenoid sarcoidosis can present as small, flattopped, skin-colored to erythematous papules; however, it can be differentiated from lichen planus by a lack of overlying white lacy marks (Wickham striae). This cutaneous presentation has been reported most often in children, can be localized or extensive, and can be eruptive in nature.…”

Section: Less Common Morphologiesmentioning

confidence: 99%

Cutaneous Sarcoidosis

Wanat

Rosenbach

2015

Clinics in Chest Medicine

109

View full text Add to dashboard Cite

The skin is the second most common organ affected in sarcoidosis, which can affect patients of all ages and races, with African American women having the highest rates of sarcoidosis in the United States. The cutaneous manifestations are protean and can reflect involvement of sarcoidal granulomas within the lesion or represent reactive non-specific inflammation, as seen with erythema nodosum. Systemic work-up is necessary in any patient with cutaneous involvement of sarcoidal granulomas, and treatment depends on other organ involvement and severity of clinical disease. Skin-directed therapies are first line for mild disease, and immunomodulators or immunosuppressants may be necessary.

show abstract

Section: Less Common Morphologiesmentioning

confidence: 99%

Cutaneous Sarcoidosis

Wanat

Rosenbach

2015

Clinics in Chest Medicine

109

View full text Add to dashboard Cite

show abstract

“…Blockade of tumour necrosis factor (TNF) has been reported as one of the most promising therapies and is widely used in the management of various inflammatory diseases such as psoriasic arthritis [4,11]. Internationally, there are three agents available as specific TNF antagonists: a soluble receptor fusion protein (etanercept), a chimeric monoclonal antibody (infliximab) and a human monoclonal antibody (adalimumab) [11].…”

Section: Discussionmentioning

confidence: 99%

“…Internationally, there are three agents available as specific TNF antagonists: a soluble receptor fusion protein (etanercept), a chimeric monoclonal antibody (infliximab) and a human monoclonal antibody (adalimumab) [11].…”

Section: Discussionmentioning

confidence: 99%

“…Activated CD4+ T cells generate interleukin-2 and interferon-γ, which combined with TNF-a, secreted by activated macrophages, promote the formation of granuloma [11].…”

Section: Discussionmentioning

confidence: 99%

“…It has been noted that cytokine imbalance due to neutralization of peripheral TNF-a could lead to the development of other autoimmune diseases related to anti-TNF-a agents, such as sarcoidosis and 'lupus-like' syndrome, by permitting the activation of specific autoreactive T cells [11].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy

Christoforidou

Goudakos

Bobos

et al. 2013

American Journal of Otolaryngology

View full text Add to dashboard Cite

Sarcoidosis

Marcoval,

Mañá

2016

Rook's Textbook of Dermatology, Ninth Edition

View full text Add to dashboard Cite

Sarcoidosis is an antigen‐mediated disease of unknown aetiology characterized by the presence of non‐caseating epithelioid cell granulomas in multiple organs. It involves mainly the lungs, mediastinal and peripheral lymph nodes, eyes and skin. Less frequent but usually severe manifestations can occur in the liver, spleen, central nervous system, heart, upper respiratory tract and bones. Cutaneous lesions of sarcoidosis may be specific, showing histopathologically sarcoid granulomas, or non‐specific, mainly erythema nodosum. Cutaneous lesions are frequently the presentation of the disease and skin biopsy enables early diagnosis. Moreover, some types of lesions have prognostic significance and may help to predict the outcome of the systemic disease.

show abstract

Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis

Abstract: A 38-year-old woman developed clinical, biochemical, radiological and histopathological evidence of cutaneous and pulmonary sarcoidosis 5 months after commencing adalimumab for chronic plaque psoriasis. Signs and symptoms resolved within 3 months of cessation of adalimumab.

Cited by 21 publications

References 9 publications

Cutaneous Sarcoidosis

Cutaneous Sarcoidosis

Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy

Sarcoidosis

Contact Info

Product

Resources

About